Latest News
- June 05, 2025Join CBCC at CPHI China 2025
- June 02, 2025Successfully completed a Phase 1a study for a US-based Innovator Biotech Company!
- May 26, 2025ANDA application for Paclitaxel Injection (Albumin bound) supported by CBCC has received Marketing Authorization from the USFDA
- May 20, 2025We’re Exhibiting at BIO 2025! Visit our booth #3480
- May 15, 2025Join CBCC Global Research at #ASCO25
Webinar: Overview of the 505(b)(2) regulatory pathway for NDA
Keen on learning best practices, seize opportunities, and overcome challenges linked to IND submissions for products which fall under the 505(b)(2) regulatory pathway?
Access to the latest webinar on:
Overview of the 505(b)(2) regulatory pathway for NDA
Webinar Link: https://www.youtube.com/watch?v=dXW5UA9TFKA
Speakers:
Dr. Sandeep Singh (VP – Clinical Operations & Regulatory Affairs, CBCC Global Research)
Ankit Parikh (Senior Manager – Medical Writing & Regulatory Affairs, CBCC Global Research)
Moderator:
Manoj Bharathi (Director – Corporate Development, CBCC Global Research)
In this webinar, our expert will cover the unique components and customizations involved in 505(b)(2) IND submissions and study requirements.
You will learn:
Underlying common bottlenecks, regulatory requirements, as well as mitigating risk while charting out plans to stay ahead of timelines.